Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum

Rev Gastroenterol Disord. Winter 2003;3(1):31-8.


Oxaliplatin is a useful agent in combination with 5-fluorouracil/leucovorin for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first-line therapy (a combination of bolus 5-fluorouracil/leucovorin and irinotecan). Oxaliplatin works by disrupting DNA replication and transcription and is cell-cycle nonspecific. In vitro, oxaliplatin has shown activity against numerous tumor lines, but it has only been approved for the treatment of metastatic carcinoma of the colon or rectum.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / secondary
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / adverse effects
  • Organoplatinum Compounds / therapeutic use*
  • Oxaliplatin
  • Product Surveillance, Postmarketing
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / secondary
  • Treatment Outcome


  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin